Consequently, in addition to the lack of evaluation of the tumorigenic capacity of cells with all surface marker combinations involving our four markers, CD24, CD44, CD54, and EpCAM, the limitations of this study are related to loss of contact with patients diagnosed with GC who were included in this protocol, since follow-up to determine patient survival can be complicated. The gene discussed is ICAM1; the disease is gastric cancer.